Navigation Links
Phylonix granted broad European patent for transplanting human cells into zebrafish
Date:12/18/2007

Cambridge, MA -- December 18, 2007 -- Phylonix Pharmaceuticals today announced that it recently received a broadly issued European patent EP 1 135 531 B1: Methods for Introducing Heterologous Cells into Fish. The patent, which has issued in key European countries, encompasses 68 claims, including transplanting stem cells, cancer cells and pathogens. In addition, neurons, chondrocytes, renal and hepatic cells can be transplanted in zebrafish and effects of growth factors or cytotoxic agents can be assessed. Claims also cover recovering cells for potential tissue engineering or transplantation applications. Many of these claims have issued previously in the United States and other countries.

This award complements our previously issued patents for assessing angiogenesis, apoptosis and toxicity in zebrafish, and use of high-throughput screening methods such as microplate analysis, commented Patricia McGrath, Phylonix President and Chief Executive Officer.

Cells that proliferate in their native environment also proliferate when transplanted into zebrafish; cells that are incapable of proliferating in their native environment usually do not proliferate in zebrafish.

Advantages of Zebrafish for Transplantation

Currently, the mouse is the model system of choice for cell transplantation assays. However, to prevent cell rejection, transplantation of human cells must be performed using immunosuppressed mice and these animals are expensive to develop and maintain. In comparison, cell transplantation in zebrafish larvae is simple and cost effective, and immunosuppression is not necessary.

There are several additional advantages of using zebrafish for transplantation assays. All essential components of vertebrate form and organ development are mimicked in the transparent zebrafish and their molecular basis is either identical or similar, underscoring the potential for use in research on human diseases. Due to the small size of zebrafish larvae, it is possible to rapidly analyze and or recover transplanted cells. Zebrafish larvae are transparent facilitating direct microscopic observation of a number of physiological processes within the cells. Zebrafish can be cultured in solution facilitating contacting transplanted cells with drugs or growth factors. Microliters of drug are required for zebrafish compared with milliliters per mouse. Standard microtiter plate readers can be used for measurement, making this format particularly attractive for high throughput drug screening. Phylonix and others have demonstrated that for many compounds, results in zebrafish correlate with results in other animal models as well as with results in humans.


'/>"/>

Contact: Edward O'Lear
ed.olear@phylonix.com
617-441-6700
Phylonix Pharmaceuticals
Source:Eurekalert

Related medicine news :

1. NIH awards Phylonix phase II SBIR to develop zebrafish models for eye diseases
2. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
3. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
4. USC granted $8.4 million for autism research
5. Aida Granted Additional Anti-Cancer Patent
6. CME LLC Granted Five-Year Full Approval by the American Psychological Association
7. ActiPatch(TM) Granted Market Clearance by the Food & Drug Administration in the Kingdom of Jordan
8. TREANDA New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Status by FDA
9. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
10. Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS
11. Broad-based group of physicians calls for improvement in stroke treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... As health professionals work to improve their approach to healthcare, there ... more than filling out a survey; in many cases health professionals and patients are ... care and research on the importance of active engagement with patients and members of ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, ... guideline updates for the primary prevention of cardiovascular diseases during the 15th ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional women, ... towards gender equality at their inaugural Summit in New York City in June. The ... social audience of over 3 million. To watch the Mobilize Women video, click ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
Breaking Medicine News(10 mins):
(Date:10/7/2017)... IRVING, Texas , Oct. 6, 2017   ... industry with more than $100 billion in purchasing power, ... industry news and information. The Newsroom is ... chain and industry trends, infographics, expert bios, news releases, ... Besides having access to a wealth of resources at ...
(Date:10/2/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... , and named its founder as Diplomat,s chief information ... Tennessee , will operate under Diplomat subsidiary Envoy ... for health care partners to include IT outsourcing, consulting, ... "In an interoperable world, technology delivers comprehensive insight and ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
Breaking Medicine Technology: